Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,246,898
  • Shares Outstanding, K 92,381
  • Annual Sales, $ 308,870 K
  • Annual Income, $ -1,597 M
  • 60-Month Beta 0.86
  • Price/Sales 93.37
  • Price/Cash Flow N/A
  • Price/Book 7.15
Trade BGNE with:

Options Overview

Details
  • Implied Volatility 54.68%
  • Historical Volatility 81.58%
  • IV Percentile 78%
  • IV Rank 60.22%
  • IV High 67.37% on 07/27/21
  • IV Low 35.48% on 05/28/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 130
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 2.51
  • Today's Open Interest 3,095
  • Open Int (30-Day) 1,621

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -3.71
  • Number of Estimates 3
  • High Estimate -2.31
  • Low Estimate -4.42
  • Prior Year -4.31
  • Growth Rate Est. (year over year) +13.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
250.19 +30.34%
on 07/26/21
338.73 -3.73%
on 07/13/21
-13.16 (-3.88%)
since 07/02/21
3-Month
250.19 +30.34%
on 07/26/21
368.45 -11.49%
on 06/01/21
-17.44 (-5.08%)
since 04/30/21
52-Week
207.96 +56.81%
on 08/10/20
388.97 -16.16%
on 02/16/21
+117.10 (+56.03%)
since 07/31/20

Most Recent Stories

More News
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA(R) (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia

--SEQUOIA is the second positive global Phase 3 trial of BRUKINSA in chronic lymphocytic leukemia, following ALPINE in relapsed or refractory setting

BGNE : 327.42 (+3.42%)
BeiGene Announces Approval in Canada of BRUKINSA(R) (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients...

BGNE : 327.42 (+3.42%)
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

REGN : 577.58 (+0.52%)
NVS : 92.26 (-0.14%)
BMRN : 77.38 (+0.85%)
BGNE : 327.42 (+3.42%)
BeiGene Announces the Approval in China of KYPROLIS(R) (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products...

BGNE : 327.42 (+3.42%)
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE)...

BGNE : 327.42 (+3.42%)
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

--Topline Phase 1 results with single-agent LYT-200 expected in the fourth quarter of 2021

BGNE : 327.42 (+3.42%)
PRTC : 47.69 (-0.65%)
PRTC.LN : 325.000 (+1.09%)
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced...

RARE : 80.71 (+1.10%)
BGNE : 327.42 (+3.42%)
MTEM : 7.10 (+1.43%)
LEGN : 43.10 (+0.16%)
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

--Tislelizumab receives its first approval in liver cancer in previously treated hepatocellular carcinoma

BGNE : 327.42 (+3.42%)
BeiGene Announces China NMPA Approval of BRUKINSA(R) (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA(R) (zanubrutinib) has received...

BGNE : 327.42 (+3.42%)
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the...

BGNE : 327.42 (+3.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 329.12
2nd Resistance Point 323.74
1st Resistance Point 320.16
Last Price 327.42
1st Support Level 311.20
2nd Support Level 305.82
3rd Support Level 302.24

See More

52-Week High 388.97
Last Price 327.42
Fibonacci 61.8% 319.82
Fibonacci 50% 298.46
Fibonacci 38.2% 277.11
52-Week Low 207.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar